What we doState-of-the-art biotechnology
centered on antibody engineering

Areas of focus

Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to
human health and well-being worldwide through innovative drug discovery and
global commercialization, driven by state-of-the-art antibody technologies,
in the core therapeutic areas of oncology, nephrology,
central nervous system and immunology.

Cutting-edge biotechnology
centered on antibody
engineering technology

Nephrology Nephrology
Immunology & Allergy Immunology & Allergy
Oncology Oncology
Central Nervous System Central Nervous System

Technology-driven drug discovery

The novel drug discovery of Kyowa Kirin is firmly
supported by the exquisite experience and
technologies in research, development and
manufacture of biologics, and by open
innovation.
This unique style of drug discovery is
what we call technology-driven drug discovery,
focused
on the key technologies below.

Pipeline

Numerous promising pharmaceutical
candidates are emerging from our
development pipelines.
They are the result of our
never-ending efforts in honing the edge of our
state-of-the-art
technologies and deliver
innovation in medical care.

  • Since the development of KW-3357 for preeclampsia was discontinued in Japan, the relevant information was deleted from this table.
  • Our main progress from December 31, 2023 are as follows.
    • In January 2024, we started phase Ⅰ clinical trial of KK2269 for treatment for solid tumor in the oncology field in Japan and North America.
    • In January 2024, we started phase Ⅱ clinical trial of KHK4951 (generic name : tivozanib) for treatment for diabetic macular edema in the other field in Japan, North America, South Korea, and Australia.

Partnerships

We are open and flexible to strategic collaborations
and partnerships
with pharmaceuticals, biotech,
and academia partners.

ADARE pharmaceuticals™ Allakos genomic medicine™ Alnylam PHARMACEUTICALS AMGEN ardelyx® AM Pharma ardelyxargenx astellas Leading Light for Life AstraZeneca Medlmmune avalo THERAPEUTICS AVEO ONCOLOGY Biogen BORYUNG Pharmaceutical Bristol-Myers Squibb BRITANNIA PHARMACEUTICALS LTD Cantergia CHUGAI Roche A member of the Roche group Daiichi-Sankyo Dexa Medica Expertise for the Promotion of health Eisai first PHARMACEUTICAL FivePrime FOBENI FUJIFILM Genentech IN BUSINESS FOR LIFE gsk HELSINN Building quality cancer care together Hisamitsu Humanigen IDC Theranostics Immunas Pharma inibsa HOSPITAL INTAS janssen JB Japan Blood Products Organization Jazz Pharmaceuticals LEO Lonza MEI pharma meiji Mitsubishi Tanabe pharma Novartis ONO ONO PHARMACEUTICAL CO.,LTD. orexo Otsuka OXFORD BioTherapeutics Phzer Pierre Fabre REATA REGiMMUNE Sandoz SERVIER Solasia Synaffix Syndax synmosa Takeda TERUMO ZERIA GROUP TILLOTTS PHARMA GI-health is our passion™ TOYOCHEM ultragenyx pharmaceutical Winhealth Pharma WIDATRA ZUELLIG PHARMA making healthcare more accessible ADARE pharmaceuticals™ Allakos genomic medicine™ Alnylam PHARMACEUTICALS AMGEN ardelyx® AM Pharma ardelyxargenx astellas Leading Light for Life AstraZeneca Medlmmune avalo THERAPEUTICS AVEO ONCOLOGY Biogen BORYUNG Pharmaceutical Bristol-Myers Squibb BRITANNIA PHARMACEUTICALS LTD Cantergia CHUGAI Roche A member of the Roche group Daiichi-Sankyo Dexa Medica Expertise for the Promotion of health Eisai first PHARMACEUTICAL FivePrime FOBENI FUJIFILM Genentech IN BUSINESS FOR LIFE gsk HELSINN Building quality cancer care together Hisamitsu Humanigen IDC Theranostics Immunas Pharma inibsa HOSPITAL INTAS janssen JB Japan Blood Products Organization Jazz Pharmaceuticals LEO Lonza MEI pharma meiji Mitsubishi Tanabe pharma Novartis ONO ONO PHARMACEUTICAL CO.,LTD. orexo Otsuka OXFORD BioTherapeutics Phzer Pierre Fabre REATA REGiMMUNE Sandoz SERVIER Solasia Synaffix Syndax synmosa Takeda TERUMO ZERIA GROUP TILLOTTS PHARMA GI-health is our passion™ TOYOCHEM ultragenyx pharmaceutical Winhealth Pharma WIDATRA ZUELLIG PHARMA making healthcare more accessible